---
input_text: 'The use of extracorporeal shock wave therapy (ESWT) in treating osteonecrosis
  of the femoral head (AVNFH): a retrospective study. PURPOSE: As most of the cases
  of avascular necrosis (AVN) in Saudi Arabia is seen in young population and as literature
  showed good effect of extracorporeal shock wave therapy (ESWT) in reducing pain
  and oedema in avascular necrosis and delaying the need of surgical intervention.
  Our purpose of this study is to assess the effectiveness of ESWT in reducing pain,
  improving range of motion (ROM) and delaying the surgical intervention in patient
  with AVN of femoral head and compare our results to published literature. MATERIAL
  AND METHODS: We have treated 24 patients, 13 males and 11 females with a mean age
  of 29 years (range 14-48) with 34 hips affected. There were 14 unilateral and ten
  bilateral lesions. In our series 11 out of 24 patients (45.8%) were due to sickle
  cell disease. Other causes included idiopathic in five patients (20.8%), corticosteroids
  use and systemic lupus erythematous in three patients each (12.5% each) and post-traumatic
  AVN in two patients (8.3%). Extracorporeal shock wave therapy was implanted in FICAT
  stage I, II and III. All patients had two sessions of extracorporeal shock wave
  therapy, four to six weeks apart, each with 4000 impulses divided into four points.
  Radiological and MRI assessment were performed at regular time intervals with a
  minimum follow-up of two years. Clinical assessment was based on Visual Analog Scale
  and Harris Hip Score (HHS). The end point outcome measurement was the need for any
  operative intervention. RESULTS: Operative intervention was necessary in eight out
  of 34 hips (23.5%), within an average of 2.5 years (range 1 to 5 years). A hip salvage
  was achieved in 76.5%. Function was improved with the Harris Hip Score from a mean
  of 54.6 to 80.4 (P value using paired t test <= 0.05). Pain assessed with Visual
  Analog Scale improved from 5.73 to 2.75 (P value using paired t test <= 0.05). CONCLUSION:
  We do recommend the use of ESWT in treating AVN of bone whether of femoral head
  or other sites prior to the collapse of the articular surface. Further studies are
  needed to compare using two or more sessions as well as using four or six points
  for ESWT.'
raw_completion_output: |-
  primary_disease: Osteonecrosis of the Femoral Head (AVNFH)

  medical_actions: Extracorporeal shock wave therapy (ESWT); Radiological and MRI assessment; Clinical assessment based on Visual Analog Scale and Harris Hip Score; Operative intervention

  symptoms: Pain; Oedema; Limited range of motion (ROM)

  chemicals: 

  action_annotation_relationships: Extracorporeal shock wave therapy (ESWT) TREATS pain IN Osteonecrosis of the Femoral Head (AVNFH); Extracorporeal shock wave therapy (ESWT) TREATS oedema IN Osteonecrosis of the Femoral Head (AVNFH); Extracorporeal shock wave therapy (ESWT) TREATS limited range of motion (ROM) IN Osteonecrosis of the Femoral Head (AVNFH); Extracorporeal shock wave therapy (ESWT) PREVENTS Operative intervention IN Osteonecrosis of the Femoral Head (AVNFH)
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  Extracorporeal shock wave therapy (ESWT) PREVENTS Operative intervention IN Osteonecrosis of the Femoral Head (AVNFH)

  ===

extracted_object:
  primary_disease: MONDO:0007885
  medical_actions:
    - Extracorporeal shock wave therapy (ESWT)
    - Radiological and MRI assessment
    - Clinical assessment based on Visual Analog Scale and Harris Hip Score
    - Operative intervention
  symptoms:
    - HP:0012531
    - HP:0000969
    - Limited range of motion (ROM)
  action_annotation_relationships:
    - subject: Extracorporeal shock wave therapy
      predicate: TREATS
      object: HP:0012531
      qualifier: MONDO:0007885
    - subject: Extracorporeal shock wave therapy (ESWT)
      predicate: TREATS
      object: HP:0000969
      qualifier: MONDO:0007885
    - subject: Extracorporeal shock wave therapy (ESWT)
      predicate: TREATS
      object: limited range of motion (ROM)
      qualifier: MONDO:0007885
    - subject: Extracorporeal shock wave therapy (ESWT)
      predicate: PREVENTS
      object: Operative intervention
      qualifier: MONDO:0007885
named_entities:
  - id: MONDO:0011382
    label: sickle cell disease
  - id: CHEBI:64357
    label: rituximab
  - id: CHEBI:35341
    label: steroids
  - id: CHEBI:81579
    label: erythropoietin
  - id: MAXO:0001017
    label: Vaccination
  - id: MONDO:0007374
    label: Sickle Cell Disease (SCD)
  - id: MAXO:0000747
    label: Allogeneic hematopoietic stem cell transplantation (HSCT)
  - id: HP:0007760
    label: Sickle Cell Disease (SCD)
  - id: MAXO:0001001
    label: Gene therapy
  - id: CHEBI:35480
    label: analgesics
  - id: CHEBI:33281
    label: antibiotics
  - id: MAXO:0001077
    label: Splenectomy
  - id: MAXO:0000756
    label: Blood transfusion
  - id: MONDO:0044348
    label: Hemoglobinopathies
  - id: CHEBI:44423
    label: Hydroxyurea
  - id: HP:0001297
    label: Stroke
  - id: HP:0002863
    label: Myelodysplastic syndrome
  - id: CHEBI:28901
    label: Busulfan
  - id: CHEBI:82594
    label: Ferritin
  - id: MONDO:0000984
    label: thalassemia
  - id: MONDO:0018881
    label: myelodysplastic syndrome
  - id: HP:0002140
    label: Ischemic Stroke
  - id: MONDO:0005380
    label: avascular necrosis
  - id: MAXO:0009047
    label: total hip replacement
  - id: HP:0010885
    label: avascular necrosis
  - id: CHEBI:4027
    label: cyclophosphamide
  - id: CHEBI:41879
    label: dexamethasone
  - id: CHEBI:9570
    label: thiotepa
  - id: CHEBI:125354
    label: plerixafor
  - id: CHEBI:9168
    label: sirolimus
  - id: CHEBI:8764
    label: mycophenolate mofetil
  - id: HP:0012531
    label: Pain
  - id: MAXO:0000515
    label: Extracorporeal life support
  - id: HP:0001708
    label: Right ventricular failure
  - id: HP:0033515
    label: opioid dependence
  - id: MONDO:0005632
    label: Acute chest syndrome in sickle cell disease
  - id: HP:0001945
    label: fever
  - id: HP:0001878
    label: Hemolytic anemia
  - id: CHEBI:6121
    label: ketamine
  - id: CHEBI:17303
    label: morphine
  - id: HP:0001744
    label: splenomegaly
  - id: HP:0031274
    label: hypovolemic shock
  - id: MAXO:0000110
    label: Vitamin D supplementation
  - id: HP:0100512
    label: Vitamin D deficiency
  - id: CHEBI:27300
    label: Vitamin D
  - id: CHEBI:28940
    label: Cholecalciferol
  - id: CHEBI:29016
    label: arginine
  - id: CHEBI:18211
    label: citrulline
  - id: CHEBI:3638
    label: chloroquine
  - id: CHEBI:50733
    label: nutritional supplements
  - id: MONDO:0005570
    label: Blood disorders
  - id: MONDO:0013517
    label: beta-thalassemia
  - id: HP:0002204
    label: Pulmonary embolus
  - id: HP:0100626
    label: end-stage liver disease
  - id: MONDO:0016363
    label: Iron overload diseases
  - id: HP:0012532
    label: Chronic pain
  - id: HP:0012432
    label: Chronic fatigue
  - id: MAXO:0010203
    label: echocardiography
  - id: HP:0002870
    label: obstructive sleep apnoea (OSA)
  - id: HP:0000520
    label: Proptosis
  - id: MAXO:0000004
    label: surgery
  - id: MAXO:0000058
    label: pharmacological treatment
  - id: MAXO:0000149
    label: Hematopoietic cell transplantation (HCT)
  - id: MONDO:0006079
    label: Acute chest syndrome (ACS)
  - id: HP:0002878
    label: Acute respiratory failure
  - id: HP:0012594
    label: Microalbuminuria
  - id: HP:0000093
    label: Proteinuria
  - id: HP:0003774
    label: End-stage renal disease
  - id: CHEBI:35457
    label: angiotensin-converting enzyme inhibitor
  - id: MAXO:0000652
    label: angiotensin-converting enzyme inhibitor therapy
  - id: HP:0000112
    label: kidney disease
  - id: MAXO:0000457
    label: Pain management
  - id: HP:0001903
    label: Anemia
  - id: CHEBI:18050
    label: L-glutamine
  - id: MAXO:0000827
    label: serum ferritin measurement
  - id: HP:0001875
    label: neutropenia
  - id: CHEBI:4356
    label: <desferrioxamine (DFO)
  - id: CHEBI:17941
    label: deferiprone (DFP)
  - id: CHEBI:49005
    label: deferasirox (DFX)
  - id: CHEBI:38157
    label: iron chelators
  - id: CHEBI:68554
    label: deferiprone
  - id: CHEBI:9144
    label: silymarin
  - id: MAXO:0000750
    label: conditioning regimens (fludarabine-thiotepa-treosulfan, busulfan-cyclophosphamide)
  - id: CHEBI:82557
    label: treosulfan
  - id: HP:0100602
    label: preeclampsia
  - id: HP:0001622
    label: preterm delivery
  - id: HP:0001511
    label: intrauterine growth restriction
  - id: CHEBI:50858
    label: corticosteroids
  - id: MAXO:0000618
    label: fluid replacement therapy
  - id: HP:0001919
    label: acute kidney injury
  - id: HP:0100639
    label: erectile dysfunction
  - id: CHEBI:71940
    label: Tadalafil
  - id: CHEBI:71942
    label: PDE5 inhibitors
  - id: MONDO:0019740
    label: Acquired thrombotic thrombocytopenic purpura (aTTP)
  - id: CHEBI:24261
    label: Glucocorticoids
  - id: MAXO:0000194
    label: Opioid therapy
  - id: MAXO:0001298
    label: therapy
  - id: CHEBI:35705
    label: immunosuppressive agents
  - id: HP:0003326
    label: Myalgia
  - id: HP:0002027
    label: Abdominal pain
  - id: HP:0002315
    label: Headache
  - id: MAXO:0001479
    label: allogeneic hematopoietic stem cell transplantation
  - id: HP:0002360
    label: Sleep disturbances
  - id: HP:0012378
    label: Fatigue
  - id: HP:0001873
    label: Thrombocytopenia
  - id: CHEBI:28876
    label: Melphalan
  - id: CHEBI:61049
    label: Tacrolimus
  - id: CHEBI:44185
    label: Methotrexate
  - id: CHEBI:46195
    label: Acetaminophen
  - id: CHEBI:47381
    label: Diclofenac
  - id: HP:0000832
    label: Primary hypothyroidism
  - id: HP:0011787
    label: Central hypothyroidism
  - id: CHEBI:18248
    label: Iron
  - id: CHEBI:30660
    label: Thyroxine
  - id: HP:0001342
    label: Hemorrhagic strokes
  - id: HP:0002326
    label: Transient ischemic attack
  - id: MONDO:0044033
    label: Posterior reversible encephalopathy syndrome
  - id: HP:0001923
    label: hemolysis (reticulocytosis)
  - id: MONDO:0800385
    label: Iron overload
  - id: CHEBI:6456
    label: Lidocaine
  - id: CHEBI:75008
    label: <visual analog pain scale (VAS)>
  - id: CHEBI:41264
    label: busulfan (Bu)
  - id: HP:0025322
    label: Venous occlusive disease (VOD)
  - id: MONDO:0005399
    label: Venous thromboembolism (VTE)
  - id: HP:0002094
    label: dyspnea
  - id: MONDO:0007885
    label: Osteonecrosis of the Femoral Head (AVNFH)
  - id: HP:0000969
    label: Oedema
